$QCLS Balance Sheet | Understand Stock

$QCLS

$0.46 -$0.01 (2.33%) Close

$QCLS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current Assets
Cash and Cash Equivalents
Marketable Securities
Deposits and Other Receivables
Other Receivables
Prepaid Expenses
Total Current Assets
Non-Current Assets
Property, Plant and Equipment, net
Operating Lease Right-of-Use Asset, net
Technology License
Goodwill
Investment in Oravax Medical
Investment in Oravax, Inc.
Other Assets
Total Non-Current Assets
Total Assets
LIABILITIES
Current Liabilities
Trade and Other Payables
Due to MyMD Florida Shareholders
Deferred Compensation Payable
Due to MyMD FL Shareholders
Related Party
Total due to MyMD FL Shareholders
Operating Lease Liability
Dividends Payable
License Fees Payable
Derivative Liability
Warrant Liability
Warrant Liabilities
Total Current Liabilities

Non-Current Liabilities
Due to MyMD Florida Shareholders
Due to MyMD Florida Shareholders, net of current portion
Derivative Liability, net of current
Deferred Compensation Payable, net of current
Deferred Compensation Payable
Contingent Consideration Payable, net of current
Lease liabilities, net of current portion
Derivative Liabilities
Common Stock
Total derivative Liabilities
Warrant Liabilities
Total Non-Current Liabilities

Total Liabilities
Mezzanine Equity
Convertible Preferred Stock, value
Series F Convertible Preferred Stock
Series F-1 Convertible Preferred Stock
Series H Convertible Preferred Stock
Series I Convertible Preferred Stock
Series G Convertible Preferred Stock
Series H Convertible Preferred Stock
Convertible Preferred Stock – Discount
Series F Convertible Preferred Stock
Series F-1 Convertible Preferred Stock
Series G Convertible Preferred Stock
Total convertible Preferred Stock – Discount
Convertible Preferred Stock – Discount
Series F Convertible Preferred Stock
Series F-1 Convertible Preferred Stock
Series G Convertible Preferred Stock
Series H Convertible Preferred Stock
Convertible Preferred Stock – Derivative
Series F Convertible Preferred Stock
Total convertible Preferred Stock – Derivative
Convertible Preferred Stock – Discount
Series F-1 Convertible Preferred Stock
Series G Convertible Preferred Stock
Series H Convertible Preferred Stock
Series H Convertible Preferred Stock – Derivative
Mezzanine Equity
Series F Convertible Preferred Stock
Total Mezzanine Equity
STOCKHOLDERS’ EQUITY
Preferred stock, value
Series D Convertible Preferred Stock
Total preferred stock, value

Common Stock, par value $0.001, 1,250,000,000 shares authorized, 8,189,838 and 7,690,403 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.
Common stock No Par Value
Total common Stock, par value $0.001, 1,250,000,000 shares authorized, 8,189,838 and 7,690,403 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively.

Additional Paid in Capital
Accumulated Deficit
Common Stock
Total Stockholders’ Equity
Total Liabilities and Stockholders’ Equity

Comments